Search for: "State v. Sallie" Results 41 - 60 of 486
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Jul 2023, 3:05 am by Laurence Lai (Simmons & Simmons LLP)
  Country of origin: new European applications in 2022 v requests for unitary effect   On the other hand, proprietors from Asia and the US appear overall less enthusiastic relative to their proportion of European filings. [read post]
25 Jul 2023, 1:43 am by Matthieu Dhenne (Dhenne Avocats)
Or that the credibility of the technical effect is assessed at the priority or filing date (e.g., TGI Paris, October 6, 2009, RG n°07/16446, Teva v. [read post]
Comment The Court of Appeal noted that it was unfortunate that the trial judge was not referred to Hallen v Brabantia. [read post]
16 Jul 2023, 11:56 pm by Kluwer IP Reporter
Apparently it was also brought forward during the meeting of the EPO’s Administrative Council late June by various member states. [read post]
16 Jul 2023, 11:56 pm by Kluwer Patent blogger
Apparently it was also brought forward during the meeting of the EPO’s Administrative Council late June by various member states. [read post]
But in the meantime, it looks to be quite easy to infringe copyright. [1] Photo by davisuko on Unsplash [2] ATB Sales v Rich Energy & Ors [2019] EWHC 1207 (IPEC) More from our authors: Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 Genuine Use of Trademarks, Second Edition by Eléonore… [read post]
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
2 Jul 2023, 1:37 am by Laurence Lai (Simmons & Simmons LLP)
Whilst the companies in this top five list are all outside the EU, the 39 member states of the EPO still account for over 45.4% of all opt-outs when looking at the country of the first-named applicant or proprietor. [read post]
7 Jun 2023, 8:30 am by Guest Author
”[4] Former Clinton Administration OIRA head Sally Katzen states that  “[t]he virtues of analysis—as robust as needed, commensurate with the significance of the decision being made—are, to me, self-evident: the regulator must think through, with all available data and in a systematic and disciplined way, all the intended and unintended consequences of a proposed rule. [read post]
2 Jun 2023, 3:16 am by Kluwer IP Reporter
Read the full story here India reverts abandoned trademark applications to original status To comply with the 13 April 2023 decision of the High Court of Delhi, India, in Intellectual Property Attorneys Association (IPAA) & Anr. v. [read post]
29 May 2023, 11:43 am by Kluwer Patent blogger
Furthermore, it should not be forgotten that the participating States in the UPC and UPCA agreement are not the same and that, in the case of the UPCA, they are not all EU Member States. [read post]
This post is the first of four looking at the decision of Smith J in Lidl & another v Tesco & another [2023] EWHC 873 (Ch). [read post]
11 May 2023, 2:21 am by Aida Tohala (Bristows)
On 4 May 2023, a mere two weeks after the conclusion of the hearing, the Court of Appeal handed down its decision in Sandoz and Teva v BMS. [read post]
Case date: 03 March 2023 Case number: No. 22-1041 Court: United States Court of Appeals, Fourth Circuit A full summary of this case has been published on Kluwer IP Law. [read post]